# A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

> **NCT06688045** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT06688045
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2024-01-06
- **Final completion:** 2024-01-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06688045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06688045, "A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06688045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*